As part of an initiative to engage the healthcare community in preventing and reducing fraud and abuse in federal healthcare programmes, the US Office of Inspector General (OIG) has drafted a guidance document that sets out the fundamental principles of internal compliance programmes for pharmaceutical manufacturers1. The guidance suggests that the following elements need to be considered when developing and implementing an effective compliance programme:
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?